News Release: July 16, 2025
Vascular endothelial growth factor (VEGF) price trend in past five years and factors impacting price movements
Over the past five years, the Vascular Endothelial Growth Factor (VEGF) market has witnessed dynamic changes in price trends influenced by several key factors such as production costs, regulatory policies, technological advancements, market competition, and the global demand-supply balance.
In 2020, the average global price for Vascular Endothelial Growth Factor (VEGF) was approximately $11,200/MT. The onset of the COVID-19 pandemic led to a significant disruption in the supply chain and a spike in production costs due to labor shortages and restricted transportation. This contributed to a sharp increase in VEGF pricing during the second half of the year. By the end of 2020, prices had risen to about $12,300/MT.
Moving into 2021, the market saw gradual normalization. The global pharmaceutical industry resumed operations at pre-pandemic levels. However, high demand for VEGF-based therapies for oncology and ophthalmology applications kept prices relatively high. The average price remained around $12,000–$12,500/MT through the year. Additionally, several biopharmaceutical companies expanded production capacity, anticipating long-term growth in the VEGF segment, which created a slight surplus in the second half of the year.
In 2022, prices began to stabilize further, averaging around $11,800/MT. This decline was partly attributed to increased competition and improved manufacturing efficiencies. Countries like China and India ramped up their domestic production, which increased global availability and introduced price competition. The expanded presence of biosimilars and alternative VEGF-based treatments also played a key role in moderating the price trend.
The year 2023 was marked by more volatility. Prices started at $11,900/MT and peaked mid-year at around $12,600/MT due to increased raw material costs and a temporary ban on exports from key Asian manufacturers following new regulatory inspections. Although the market adjusted in the final quarter, the annual average closed higher than 2022 at about $12,200/MT. The uptick was also driven by increased clinical trials and drug development programs focused on VEGF inhibitors.
In 2024, the Vascular Endothelial Growth Factor (VEGF) price trend demonstrated resilience in the face of inflationary pressures and rising logistics costs. Pricing started at around $12,300/MT in Q1 but fell slightly by year-end to $12,000/MT. Notably, bulk buyers from North America and Europe negotiated long-term contracts, thereby avoiding price surges caused by sporadic market disruptions.
By 2025, the market entered a new phase of consolidation. Technological innovations in upstream fermentation processes and the use of synthetic biology tools allowed some manufacturers to reduce production costs by as much as 10%. The average global price at the beginning of 2025 stood at approximately $11,500/MT, reflecting this cost advantage. However, the Vascular endothelial growth factor (VEGF) price news in Q2 of 2025 reported marginal hikes in price to $11,800/MT due to growing demand from the oncology sector, especially in Asia-Pacific and South America.
In conclusion, the Vascular endothelial growth factor (VEGF) price trend over the past five years has been shaped by supply chain dynamics, therapeutic demand, and advancements in production technologies. Market participants are now more focused on scalable, cost-effective manufacturing processes, which could bring about greater pricing stability in the coming years. Meanwhile, the regulatory environment and geopolitical influences will remain critical determinants of VEGF pricing through the rest of 2025 and beyond.
Vascular Endothelial Growth Factor (VEGF) price trend and production News
Vascular endothelial growth factor (VEGF) price trend quarterly update in $/MT: (estimated quarterly prices)
Q1 2025: $11,500/MT
Q2 2025: $11,800/MT
Q3 2025: $12,000/MT (forecasted)
Q4 2025: $12,100/MT (forecasted)
These quarterly updates reflect moderate growth, driven by stable raw material availability and expanding end-user markets. Vascular endothelial growth factor (VEGF) price news continues to highlight the role of improved logistics and expanded manufacturing capacities across Asia and North America in tempering significant price escalations.
Global Vascular endothelial growth factor (VEGF) import-export Business Overview
The global Vascular Endothelial Growth Factor (VEGF) import-export landscape in 2025 is characterized by regional production imbalances, stringent pharmaceutical regulations, and strategic alliances aimed at securing supply chains. As a high-value biopharmaceutical ingredient, VEGF sees significant cross-border trade among leading pharma hubs in North America, Europe, and Asia-Pacific.
The largest exporters of Vascular endothelial growth factor (VEGF) are the United States, Germany, China, and India. The U.S. leads due to its robust biotechnology ecosystem and FDA-approved manufacturing facilities. With an estimated export volume of 1,200 MT in 2024, the U.S. supplied VEGF primarily to Latin America, Canada, and select European markets. Germany follows closely, supplying high-purity VEGF to countries in Central and Eastern Europe, with a focus on hospital and research-based consumption.
China, while a key exporter, is also one of the top importers due to varying levels of purity requirements for clinical trials and large-scale drug production. Chinese firms typically import VEGF from the EU and the U.S. for premium applications, while exporting locally manufactured VEGF for industrial and research purposes. India’s exports rose sharply in 2023–2024, driven by cost-competitive manufacturing and strong demand in Middle Eastern and Southeast Asian markets.
Meanwhile, countries like Brazil, South Africa, and Turkey have emerged as new entrants in the Vascular endothelial growth factor (VEGF) import market. With the expansion of healthcare coverage and oncology infrastructure, these nations are increasing their import volumes. In 2024, Brazil’s import volume stood at 540 MT, while Turkey imported approximately 320 MT. South Africa’s imports remain lower but are growing steadily year-on-year.
Vascular endothelial growth factor (VEGF) production hubs are strategically focusing on biosafety and quality certification to gain a competitive edge in exports. European manufacturers have increased their investment in GMP-compliant facilities, aiming to capture more of the high-margin pharmaceutical-grade VEGF market. At the same time, Asian producers are scaling their production to cater to biosimilar developers and contract manufacturing organizations.
As of 2025, global Vascular endothelial growth factor (VEGF) sales volume for import-export trade is expected to exceed 9,000 MT, a 7% increase from 2024 levels. This growth is driven by both increasing therapeutic application and greater research activity in regenerative medicine and cancer biology. In particular, Vascular endothelial growth factor (VEGF) sales volume in Latin America and Southeast Asia has outpaced traditional markets due to favorable import policies and rising investments in healthcare infrastructure.
One significant trend shaping VEGF trade is bilateral agreements and long-term procurement contracts. For instance, European pharmaceutical giants have signed three- to five-year agreements with South Korean and Japanese manufacturers to mitigate risks associated with supply disruption. Similarly, large biotech firms in the U.S. are increasingly sourcing from Indian CMOs to reduce costs while maintaining quality.
Vascular endothelial growth factor (VEGF) price news in 2025 also points to potential price fluctuations based on import tariffs. Recent trade tensions between key exporting nations have led to speculation of tariffs that may impact VEGF pricing in Q3 and Q4 2025. Companies are exploring regional warehousing strategies to buffer against such risks.
Technological innovation continues to support global trade efficiency. Digital documentation systems and AI-based quality assessment tools are now being used to streamline customs clearance and regulatory compliance. This is especially relevant for countries with strict pharmaceutical import policies, such as Japan and Australia, where real-time tracking and compliance play a crucial role in trade approval.
Additionally, the Vascular endothelial growth factor (VEGF) production process is seeing transformation due to advances in synthetic biology and automation. Countries with developed biotech sectors are benefiting from shorter production cycles and improved yields, which enhance their export capacity.
In conclusion, the Vascular endothelial growth factor (VEGF) import-export market in 2025 is undergoing rapid evolution. With rising global demand, shifts in production strategies, and regulatory alignment, international trade in VEGF is set to expand further. The price trend, production capacity, and logistical capabilities will continue to define competitiveness in the global marketplace, making it imperative for stakeholders to stay ahead of the curve through innovation and collaboration.
For further details and to request a sample report, visit the full analysis on https://datavagyanik.com/reports/vascular-endothelial-growth-factor-vegf-market-size-production-sales-average-product-price-market-share-import-vs-export/
Vascular Endothelial Growth Factor (VEGF) Production Trends by Geography
The production landscape of Vascular Endothelial Growth Factor (VEGF) is shaped by regional infrastructure, regulatory conditions, investment in biotechnology, and access to skilled talent. In 2025, the global VEGF production is increasingly concentrated in key pharmaceutical and biotechnology hubs, with several countries leading the charge due to advanced capabilities in recombinant protein manufacturing and biopharmaceutical innovation.
The United States remains the leading producer of VEGF, backed by its strong biopharma ecosystem and well-established research and development institutions. The country houses some of the world’s top contract development and manufacturing organizations (CDMOs) and biotechnology firms with large-scale capabilities for producing growth factors like VEGF. In 2025, several new facilities have come online, focusing on scalable recombinant protein production, using optimized cell lines and fermentation technologies. These facilities cater to both domestic pharmaceutical use and export demands. The U.S. government’s support for biotech R&D continues to fuel innovation in protein purification and yield enhancement processes.
Europe, especially countries like Germany, Switzerland, and the Netherlands, plays a significant role in VEGF production. German manufacturers are particularly renowned for high-purity VEGF products used in clinical and therapeutic applications. Regulatory standards across the European Union ensure consistent quality and GMP-compliance, which makes European VEGF highly competitive in the global market. The continent also benefits from growing demand for VEGF in cancer therapies and age-related macular degeneration treatments, prompting further investment in production facilities.
In Asia, China and India have emerged as critical production centers for VEGF, largely due to lower labor costs, expanded biomanufacturing zones, and increasing investments in life sciences. China’s production capabilities have expanded with support from national biotech initiatives, resulting in a surge in VEGF volume production in provinces such as Jiangsu and Zhejiang. Domestic demand is growing due to the country’s focus on biotechnology-driven healthcare reform. At the same time, Chinese producers are enhancing production efficiency using innovative upstream and downstream processing technologies.
India’s role in VEGF production is also rising, especially in the contract manufacturing segment. Indian firms are increasingly exporting VEGF to Europe, Latin America, and Africa, benefiting from cost efficiencies and upgraded facilities. Indian companies are also investing in biosimilar development, many of which require large-scale VEGF production. As a result, VEGF production in India in 2025 has seen a year-on-year growth of over 10%.
South Korea and Japan are also important players in Asia. Japan maintains high standards in biotechnology manufacturing, with VEGF being produced for specialized therapeutic markets. South Korea has focused on biopharmaceutical innovation, with new investments supporting the scale-up of growth factor production for regenerative medicine and oncology applications. Both countries rely heavily on innovation, using advanced bioreactor systems and genetically engineered cell platforms for VEGF synthesis.
In Latin America, Brazil is emerging as a modest producer of VEGF, supported by rising domestic demand and partnerships with European biotechnology firms. Although the region does not yet match the scale of North America or Asia, government incentives and local biotech startup activity are gradually expanding Brazil’s production capacity.
In the Middle East and Africa, VEGF production remains limited, with most countries depending on imports. However, targeted efforts are being made in countries like the United Arab Emirates to establish local biopharma capabilities. These are still in early stages, focusing on smaller-scale production for research institutions and clinical trials.
Australia is another region contributing to VEGF production, particularly for academic research and clinical applications. With support from government health agencies, Australian institutions are developing production processes suitable for customized and precision therapies involving VEGF.
Globally, the shift toward decentralized manufacturing, increased use of modular bioreactors, and adoption of AI in process monitoring are common trends. Regional players are seeking to reduce dependency on imports by enhancing local production capacities. At the same time, cross-border technology partnerships and licensing agreements are helping newer markets adopt advanced production techniques.
In conclusion, Vascular Endothelial Growth Factor (VEGF) production in 2025 is marked by geographic diversification and technological progress. The U.S., Europe, China, and India are at the forefront, while other regions are strategically building up their production capabilities to meet rising therapeutic demand.
Vascular Endothelial Growth Factor (VEGF) Market Segmentation
Segments of the VEGF market:
- By Application
- Oncology
- Ophthalmology
- Cardiovascular Diseases
- Regenerative Medicine
- Others
- By Product Type
- Recombinant Human VEGF
- VEGF Inhibitors (Antibodies and Fusion Proteins)
- Biosimilars
- By End User
- Hospitals
- Biopharmaceutical Companies
- Academic and Research Institutes
- Contract Research Organizations (CROs)
- By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Explanation of Leading Segments
The Vascular Endothelial Growth Factor (VEGF) market is segmented across multiple dimensions, reflecting the compound’s varied applications in therapeutics, research, and drug development. In 2025, certain segments have emerged as dominant drivers of growth, owing to medical demand, innovation, and supportive healthcare policies.
The oncology segment leads the application-based segmentation. VEGF is a critical target in the treatment of various cancers, particularly those involving angiogenesis such as renal cell carcinoma, colorectal cancer, and non-small cell lung cancer. Anti-VEGF therapies like bevacizumab have been foundational in cancer treatment protocols, and the demand continues to grow with increasing cancer prevalence. In 2025, oncology accounts for more than 50% of total VEGF-related therapeutic usage globally. New research is exploring combination therapies involving VEGF inhibitors and immuno-oncology agents, further expanding this segment’s potential.
Ophthalmology is another strong segment, particularly in the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy. Intravitreal injections of VEGF inhibitors have become the standard of care, and the patient base continues to grow, especially among aging populations. Markets in Japan, the U.S., and parts of Europe show strong demand for anti-VEGF formulations specifically developed for ocular delivery. Innovations in drug delivery systems, such as sustained-release implants, are further reinforcing this segment’s dominance.
The cardiovascular diseases segment is still developing, but there is increasing interest in leveraging VEGF’s angiogenic properties for therapeutic revascularization in ischemic heart disease. Research programs are evaluating gene therapies and cell therapies that use VEGF as a biological agent to stimulate new blood vessel growth in damaged tissues. While still largely in the trial phase, this segment holds promise for future growth.
Regenerative medicine is emerging as a high-potential area. VEGF is widely used in tissue engineering and stem cell therapy to enhance vascularization of grafts and engineered tissues. Researchers across North America, South Korea, and the EU are actively investigating ways to integrate VEGF in bioengineered constructs. In 2025, regenerative medicine applications of VEGF are more common in academic and early-stage clinical settings, but commercial applications are gradually increasing.
By product type, VEGF inhibitors form the largest market share. These include monoclonal antibodies, receptor fusion proteins, and small molecules that block VEGF signaling pathways. Biopharmaceutical companies continue to develop novel inhibitors with improved half-life and specificity. Recombinant human VEGF is primarily used in research and regenerative medicine applications. With the rise of advanced manufacturing platforms, production of recombinant VEGF is becoming more cost-efficient and scalable.
Biosimilars represent a fast-growing product category. As patents on key VEGF inhibitors expire, biosimilar manufacturers are entering the market, especially in Asia and Latin America. These alternatives are priced more competitively, helping to improve treatment accessibility in cost-sensitive markets. India, South Korea, and Brazil are particularly active in biosimilar development.
In terms of end users, hospitals remain the largest consumers of VEGF-based therapies due to their role in administering oncology and ophthalmology treatments. These institutions also lead in adopting new biologics and participating in clinical trials. Biopharmaceutical companies are major consumers of VEGF for use in both clinical and preclinical drug development. With growing investment in biologics, these companies are scaling up VEGF use for manufacturing and innovation pipelines.
Academic and research institutes use VEGF extensively for basic science and translational research. These institutions focus on understanding angiogenesis, wound healing, and new drug delivery methods. The demand from research institutes is especially high in North America and Europe, where government and private grants support biotechnological innovation.
Contract Research Organizations (CROs) are increasingly involved in VEGF-related projects, offering services ranging from preclinical testing to clinical trial management. As outsourcing trends grow in the pharmaceutical sector, CROs are handling more VEGF-related studies for global sponsors.
Regionally, North America dominates the VEGF market in terms of both production and consumption. The region benefits from strong R&D, advanced healthcare systems, and high adoption of biologics. Europe follows closely, with increasing demand driven by demographic changes and expansion in personalized medicine. Asia-Pacific is the fastest-growing region due to increasing healthcare access, growing biosimilar adoption, and supportive government policies. Latin America and the Middle East are still emerging markets but are experiencing growth in VEGF consumption due to expanding healthcare infrastructure.
In summary, the Vascular Endothelial Growth Factor (VEGF) market is segmented across diverse applications and user groups, with oncology, ophthalmology, and biosimilars leading in growth. Regional differences in healthcare systems and production capacities shape the overall market dynamics, and continued investment in innovation is expected to drive further expansion across all major segments.